The ability of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) to lower blood pressure (BP) is well established. ACE inhibitors (ACE-Is) have also been shown to improve the prognosis of a broad range of patients at high cardiovascular risk, including those with heart failure, post-myocardial infarction (MI), and nephropathy. These benefits suggest that interrupting the reninangiotensin-aldosterone system (RAAS) with ACE-Is has a widespread vasculoprotective effect, provided that BP is also adequately controlled. Evidence that RAAS blockade by ARBs also improves long-
Introduction
The risks associated with high blood pressure (BP) and the benefits of treatment have been known for decades, but hypertension remains inadequately diagnosed and undertreated. 1 Elucidation of the role of the renin-angiotensinaldosterone system (RAAS) in the pathophysiology of hypertension led to the development of pharmacological agents that specifically interfere with the RAAS, the angiotensin-converting enzyme (ACE) inhibitors and the angiotensin II (Ang II) type 1 (AT 1 )-receptor blockers (ARBs).
Efficacy, duration of action, organ-specific effects and tolerability are the main considerations when choosing an antihypertensive drug. ACE inhibitors (ACE-Is) prevent the conversion of angiotensin I to Ang II, the principal active hormone of the RAAS. As well as being effective in hypertension,ACE-Is are also indicated for heart failure, post-myocardial infarction (MI), and nephropathy. Inhibition of ACE, a non-specific enzyme, also prevents the catabolism of other biologically active peptides, such as bradykinin, substance P and prostaglandins. Although elevated levels of these molecules may augment the therapeutic response, 2 they may also cause side-effects, such as cough and angioedema, which often result in treatment discontinuation. 3 Furthermore, some patients on ACE-Is develop a reactive and persistent increase in Ang II levels due to activation of ACE-independent pathways of Ang II production. 4 The ARBs (losartan, 5 candesartan cilexetil, 6 valsartan, 7 telmisartan, 8 eprosartan, 9 olmesartan medoxomil 10 and irbesartan 11 ) have similar antihypertensive efficacies to ACE-Is, calcium channel blockers and β-blockers, 12 but a differentiating feature is their excellent tolerability. The sideeffect profiles of ARBs are indistinguishable from that of placebo and, unlike ACE-Is, they are not associated with cough. 13 Despite the proven BP-lowering efficacy of ARBs, long-term outcome trial data showing that they reduce cardiovascular events are still awaited, as is information on their performance in indications other than hypertension. Since ARBs and ACE-Is both target the RAAS, ARBs might be expected to be useful for the same indications as ACE-Is. One could speculate that these effects would be even greater than ACE-Is, owing to the more complete RAAS blockade by ARBs, which act at the level of the Ang II receptor.
This review will evaluate the results of the ARB outcome studies that have been completed, discuss the clinical importance of planned and ongoing trials, and consider how the results of these studies will influence the use of ARBs in future clinical practice.
Hypertension
Many short-term studies have confirmed the antihypertensive efficacy of ARBs. Ongoing clinical trials are now examining whether this translates into long-term benefits on target-organ damage ( Table 1) .
LIFE
Left ventricular hypertrophy (LVH) occurs in nearly 40% of all individuals with hypertension and, after age, is the strongest predictor of cardiovascular disease and mortality. In the Framingham Heart Study, 45% of all cardiovascular events were preceded by electrocardiographic (ECG) evidence of LVH, and one-third of the men and one-fifth of the women died within five years of the appearance of LVH. 38 Experimental studies and clinical trials support the theory that blocking the RAAS is an effective means of promoting the regression of LVH. 39 The recently reported Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial was a randomised, double-blind, parallelgroup study comparing the effects of losartan and atenolol on cardiovascular morbidity and mortality in high-risk patients with hypertension and LVH. 14 Figure 1 ).The difference was due mainly to a 25% reduction (95% CI 63-89%, p=0.001) in the risk of stroke in the losartan group.As with ramipril in the Heart Outcomes Prevention Evaluation (HOPE) study, the incidence of new-onset diabetes was reduced, being 25% lower (95% CI 63-88%, p=0.001) in the losartan group than in the atenolol group. Losartan was also better tolerated than atenolol.
Thus, LIFE shows that RAAS blockade with an ARB (losartan) has a greater impact on cardiovascular morbidity and mortality than β-blockade with atenolol, despite an equivalent reduction in BP. Taken together with the results of HOPE, it would seem that interruption of the RAAS confers protection against the detrimental effects of Ang II on the vasculature that are additional to the reduction in BP.
SCOPE
As well as conventional cardiovascular endpoints, the Study on COgnition and Prognosis in the Elderly (SCOPE) has evaluated the effects of antihypertensive treatment on cognitive function. 15, 16 This latter objective is based on observations from longitudinal studies suggesting that hypertension predisposes to cognitive impairment and dementia later in life, especially in untreated individuals or those with poorly controlled BP. 42, 43 SCOPE was a randomised, double-blind, parallel-group study involving 4,964 elderly patients (70-89 years of age) with mild hypertension (defined as SBP 160-179 mmHg and/or DBP 90-99 mmHg) and a Mini Mental State Examination score ≥ 24 (i.e. no dementia). 15 Treatment was with candesartan cilexetil 8-16 mg or placebo, with the addition of hydrochlorothiazide (HCTZ) 12.5 mg, to attain a BP goal of < 160/90 mmHg. After a follow-up period of two years, the effect of candesartan cilexetil on major cardiovascular events (cardiovascular death, nonfatal MI, and non-fatal stroke; primary endpoint), cognitive function, dementia, total mortality, MI, stroke, renal function, and hospitalisation was evaluated. Additional analyses on quality of life and health economics are also planned.
The preliminary results of SCOPE (as yet unpublished) were presented at the joint meeting of the International Society of Hypertension and the European Society of Hypertension in June 2002.Although there was an 11% reduction in the risk of the primary composite endpoint with candesartan cilexetil versus placebo, this was not statistically significant (p=0. 19) . Analysis of each of 
the components of the composite endpoint showed no difference between the treatment groups with regard to the incidence of cardiovascular death and MI. However, patients treated with candesartan cilexetil benefited from a significant 28% reduction (p=0.041) in the risk of a non-fatal stroke.There was also a 20% decrease in new diagnoses of diabetes with candesartan cilexetil, though this did not reach statistical significance (p=0.83). Lowering BP did not lead to a decline in cognitive function; in fact, in patients with reduced scores on the Mini Mental State Examination at baseline, the decline in cognitive function was slower in the candesartan cilexetil group than in the placebo group. SCOPE is important for several reasons. The advantages of lowering BP in elderly patients with hypertension are known, 44 but there have been no specific studies to date to assess the benefits of treating those with only mildly elevated BP, in terms of preventing cardiovascular events, stroke, and cognitive dysfunction. SCOPE has now demonstrated that treating even mild hypertension in the elderly significantly reduces the incidence of non-fatal strokes and, reassuringly, that lowering BP does not increase the risk of cognitive decline or the development of dementia.The results of SCOPE may have important implications in terms of the management of elderly patients with mild hypertension.
VALUE
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study is one of the largest intervention studies in essential hypertension and the only one comparing an ARB with a dihydropyridine calcium channel blocker. 17 This randomised, double-blind, parallel-group trial has been designed to determine whether, for an equivalent reduction in BP, valsartan is more effective than amlodipine in decreasing cardiac morbidity and mortality, all-cause mortality, cerebrovascular accidents, and end-stage renal disease.
The VALUE population comprises 15,314 hypertensive men and women, ≥ 50 years of age, at relatively high cardiovascular risk. Risk is stratified by considering age, gender, and a number of cardiovascular risk factors (smoking, diabetes, hypercholesterolaemia, LVH, proteinuria, and elevated serum creatinine), and disease factors (coronary heart disease, peripheral vascular disease, stroke or transient ischaemic attack, and LVH with ECG strain pattern). Treatment is with valsartan 80-160 mg or amlodipine 5-10 mg, with the stepwise addition of HCTZ and other antihypertensives (excluding other ARBs, calcium channel blockers, or ACE-Is) to achieve target BP (< 140/90 mmHg).
By applying a predefined risk assessment algorithm, VALUE should allow evaluation of the predictive power of a cardiovascular risk factor scale in a large population of treated hypertensive patients. This represents a unique feature of the study. VALUE will run until 1,450 patients have a primary cardiac event (cardiac mortality, non-fatal MI, hospitalisation for heart failure, or emergency procedure to prevent overt MI), which is expected to be in 2003.
Heart failure ACE-Is reduce morbidity and mortality in patients with chronic heart failure. [45] [46] [47] These benefits have been attributed, at least in part, to RAAS inhibition, although bradykinin accumulation and other mechanisms may also be important. Several clinical trials have been designed to assess whether ARBs will produce similar benefits to ACE-Is in patients with chronic heart failure (see Table 1 ).
ELITE
Losartan was the first ARB studied in patients with heart failure. The Evaluation of Losartan In The Elderly (ELITE) trial was a randomised, doubleblind, parallel-group study comparing losartan with captopril in 722 patients, ≥ 65 years of age, with symptomatic heart failure. 18, 19 Subjects received either losartan, titrated as tolerated from 12.5 to 50 mg once-daily, or captopril titrated as tolerated from 6.25 to 50 mg three times daily, for 48 weeks.
Losartan and captopril had similar effects on the primary tolerability endpoint of renal dysfunction, measured as a persistent increase in serum creatinine. However, losartan significantly reduced all-cause mortality (4.8% vs. 8.7%; p<0.05). The incidences of death or hospitalisation for heart failure or both (composite endpoint), hospitalisation for heart failure, and hospitalisation for any reason were also lower among losartan-treated patients, but these differences were not statistically significant ( Table 2) . Losartan was better tolerated than captopril, with fewer patients on losartan than on captopril discontinuing because of adverse events (12.2% vs. 20.8%; p=0.002).
Although ELITE provided some indication that ARBs might offer at least as good outcomes as ACE-Is in patients with heart failure, the study was powered primarily for safety (renal dysfunction), not mortality, and the patient numbers involved were relatively small.
ELITE II
The promising results of ELITE prompted the larger ELITE II study. 20 ELITE II was properly powered to establish whether losartan, 50 mg once-daily, was superior to captopril, 50 mg three times daily, in reducing the risk of all-cause mortality in elderly heart failure patients. A total of 3,152 patients, ≥ 60 years of age, were randomised and the median follow-up period was 1.5 years.
The findings of ELITE II were somewhat disappointing. 21 There was a non-significant trend in favour of captopril compared with losartan for allcause mortality (15.9% vs. 17.7%), sudden death or resuscitated cardiac arrest (7.3% vs. 9.0%), and the combined endpoint of all-cause mortality or hospitalisation for any cause (44.9% vs. 47.7%). On the other hand, losartan was significantly better tolerated than captopril: 9.7% of patients on losartan discontinued treatment because of adverse events compared with 14.7% of those on captopril (p<0.001). REVIEW ELITE II has only partially clarified the role of ARBs in heart failure.There is considerable debate as to whether the dose of losartan given was therapeutically equivalent to that of captopril, so a final conclusion about their comparative efficacies cannot be drawn. In addition, until data with other ARBs become available, the results of the ELITE trials should not be extrapolated to the whole class.
Val-HeFT
The Valsartan in Heart Failure Trial (Val-HeFT) evaluated the effects of valsartan on morbidity and mortality when added to conventional heart failure treatment, including ACE-Is. 22, 23 This doubleblind, placebo-controlled trial randomised 5,010 heart failure patients, ≥ 18 years of age, to add-on treatment with valsartan, 160 mg twice-daily, or matched placebo. Follow-up was for approximately two years.
Add-on valsartan had no effect on overall mortality compared with placebo (19.7% vs. 19.4%). 24 However, the incidence of the combined endpoint of all-cause mortality and morbidity (defined as the incidence of cardiac arrest with resuscitation, hospitalisation for heart failure, or need for intravenous inotropic or vasodilator therapy for ≥ 4 hours) was 13.2% lower with valsartan (28.8%) than with placebo (32.1%) (relative risk 0.87; 97.5% CI 0.77-0.97; p<0.01).This benefit was primarily attributed to a 24% reduction in hospitalisation for heart failure with valsartan (18.2%) compared with placebo (13.8%; p<0.001). New York Heart Association (NYHA) functional class, ejection fraction, and signs and symptoms of heart failure also improved significantly with valsartan compared with placebo (p<0.001). Quality of life deteriorated among patients on placebo, but not among those on valsartan (p=0.05).
An interesting post-hoc subgroup analysis was conducted according to baseline treatment.There was, unexpectedly, an adverse effect on morbidity and mortality if an ACE-I, a β-blocker and valsartan were given together, suggesting that extensive neurohormonal blockade could be harmful. On the other hand, valsartan had a striking beneficial effect on the composite endpoint of morbidity and mortality in the small sample of patients who were not on an ACE-I at baseline. In fact, based on this finding, the FDA has approved valsartan for the treatment of heart failure in patients intolerant to ACE-Is.
RESOLVD
The Randomized Evaluation of Strategies fOr Left Ventricular Dysfunction (RESOLVD) was a pilot study looking at the combination of an ACE-I with an ARB in 768 patients with symptomatic heart failure. 25 Participants had moderate-to-severe heart failure and limited exercise capacity (a 6-minute walk distance of < 500 m). Treatment was for 43 weeks with candesartan cilexetil 4, 8 or 16 mg, enalapril, 20 mg, or a combination of candesartan cilexetil, 4 or 8 mg, plus enalapril 20 mg.
At treatment end, no differences were seen between the treatment groups in terms of exercise capacity (the primary endpoint, which did not change from baseline levels), NYHA class, mortality, hospitalisation for heart failure, all-cause hospitalisation, or quality of life. 48 Ejection fraction increased slightly more with candesartan cilexetil plus enalapril (2.5%) than with candesartan cilexetil (1.5%) or enalapril (1.5%) alone, but this was not statistically significant. However, the combination appeared to be better at preventing cardiac remodelling: end-diastolic and systolic volumes increased significantly less with candesartan cilexetil plus enalapril (8+4 ml for diastolic; 1+4 ml for systolic) compared with candesartan cilexetil (27+4 ml and 18+3 ml, respectively) or enalapril (23+7 ml and 14+6 ml, respectively; p<0.01).
RESOLVD provides some indication that an ARB/ACE-I combination may be more beneficial than either drug alone in patients with heart failure in terms of preventing cardiac remodelling. Nevertheless, the findings should be interpreted with caution, since the drugs were used in sub- CHARM I is comparing a combination of candesartan cilexetil plus an ACE-I with placebo plus an ACE-I, in 2,600 patients with an ejection fraction < 40%.The ACE-I is not fixed, but depends on treatment at baseline. CHARM II is comparing candesartan cilexetil with placebo in 2,000 ACE-Iintolerant patients with an ejection fraction < 40%, and CHARM III is evaluating candesartan cilexetil versus placebo in 3,000 patients with preserved left ventricular function (ejection fraction > 40%). This latter population, comprising a high proportion of elderly patients, has not been studied extensively before.These patients will not receive an ACE-I unless they have vascular disease or are at high risk of cardiovascular events.
The primary endpoint of each trial is a composite of cardiovascular mortality or hospitalisation for heart failure. CHARM will also examine the effects of the different treatments on the incidence of cardiovascular disease, all-cause hospitalisation and resource utilisation, and pooled data from CHARM I-III will be analysed for all-cause mortality.
CHARM is the first study to involve all heart failure patients who may benefit from RAAS blockade, irrespective of their left ventricular function or tolerance to ACE-Is. It should provide important information on whether an ARB/ACE-I combination provides greater benefit than either agent alone.
Diabetes mellitus
Early and aggressive treatment of hypertension is particularly important in diabetic patients, to prevent cardiovascular disease and to minimise the progression of diabetic retinopathy and renal disease. 49 Although ACE-Is are already known to have renoprotective properties beyond their effects on BP, 50 whether or not ARBs provide similar benefits has been the subject of several randomised controlled trials (see Table 1 ).
RENAAL
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial was a double-blind, placebo-controlled study evaluating the renoprotective effects of losartan in Type 2 diabetic patients with established nephropathy. 27 The study randomised 1,513 patients to losartan, 50-100 mg, or placebo, as an add-on to their existing medication. Additional antihypertensives were allowed if BP remained > 140/90 mmHg, but concomitant treatment with ACE-Is or other ARBs was prohibited.
Recruitment into RENAAL ended in 1998, and the intended mean follow-up period was 4.5 years. The trial was, however, terminated, early in 2001, after a mean follow-up of just 3.4 years.This decision was taken on ethical grounds following publication of data from the HOPE study showing that ACE-Is reduce the incidence of cardiovascular events and overt nephropathy in patients with renal impairment, including those with diabetes. 51, 52 RENAAL has provided key evidence that an ARB can delay renal deterioration in patients with Type 2 diabetes and nephropathy. 28 Losartan reduced the risk of the primary endpoint, a composite of a doubling of serum creatinine (which approximates to a halving of the glomerular filtration rate), end-stage renal disease, or death, by 16% (p=0.02) ( Table 3) . This risk reduction remained essentially unchanged (15%) after correcting for BP (p=0.03). Losartan also significantly decreased the individual risks of a doubling of serum creatinine and end-stage renal disease (p=0.01; see Table 3 ), and reduced the risk of hospitalisation for heart failure. 
IRMA II
IRbesartan in patients with type II diabetes and MicroAlbuminuria (IRMA II) was a randomised, double-blind, placebo-controlled study designed to assess whether irbesartan could prevent the onset of diabetic nephropathy in hypertensive patients with Type 2 diabetes and microalbuminuria. 29 Participants (n=590) were 30-70 years of age, with hypertension (SBP > 135 mmHg and/or DBP > 85 mmHg), persistent microalbuminuria, and a serum creatinine concentration < 1.5 mg/dL for men and < 1.1 mg/dL for women.Treatment was with irbesartan 150 mg, irbesartan 300 mg, or placebo for two years. Additional antihypertensive therapy (excluding ACE-Is or other ARBs) was permitted. Irbesartan significantly reduced the rate of progression to overt diabetic nephropathy in patients with Type 2 diabetes and microalbuminuria ( Figure  2 ). Nephropathy developed in 19 patients on irbesartan 150 mg (p=0.08) and 10 patients on irbesartan 300 mg (p<0.001), compared with 30 patients on placebo, and normoalbuminuria was restored in more patients treated with irbesartan 300 mg than placebo (34% vs. 21%; p=0.006). Importantly, this study also showed that a high dose of an ARB may be more effective at renal protection than a low dose.
As in RENAAL, these renal benefits appeared to be largely independent of the hypotensive effect, since the average trough BP during the study was only marginally lower in the irbesartan groups compared with the placebo group: 143/83 mmHg for irbesartan 150 mg, 141/83 mmHg for irbesartan 300 mg,and 144/83 mmHg for placebo.Furthermore,the advantage in favour of irbesartan remained robust after adjusting for the achieved BP.
IDNT
The Irbesartan type 2 Diabetic Nephropathy Trial (IDNT) recruited 1,715 patients with more advanced renal disease than those in IRMA II. 30, 31 Patients had Type 2 diabetes mellitus, hypertension (SBP > 135 mmHg, DBP > 85 mmHg or documented antihypertensive treatment), proteinuria (≥ 900 mg/24-hour), and elevated serum creatinine (1.0-3.0 mg/dL in men, 1.2-3.0 mg/dL in women). Treatment was with irbesartan 75-300 mg, amlodipine 2.5-10 mg, or placebo (plus other antihypertensives [excluding ACE-Is, ARBs or calcium channel blockers] to achieve a BP of < 135/85 mmHg, or a reduction of ≥ 10 mmHg in patients with baseline SBP > 145 mmHg). Followup was for a mean of 2.6 years.
The results of IDNT showed that irbesartan has a favourable effect on renal function among patients with established renal disease. 31 The risk of the primary endpoint (a composite of a doubling of serum creatinine, the onset of end-stage renal disease, or death) with irbesartan was 20% lower than with placebo (p=0.02) and 23% lower than with amlodipine (p=0.006). Furthermore, the relative risk of a doubling of the serum creatinine concentration was 33% lower among irbesartantreated patients than placebo-treated patients (p=0.003) and 37% lower than amlodipine-treated patients (p<0.001). Again, these benefits are not explained by differences in BP between the treatment groups.Amlodipine did not decrease the relative risk of the composite endpoint or a doubling of serum creatinine compared with conventional antihypertensive treatment.
ABCD-2V
The Appropriate Blood pressure Control in Diabetes part 2 with Valsartan (ABCD-2V) trial is a randomised, double-blind, five-year continuation of ABCD. 53, 54 It is testing whether intensive DBP control (< 75 mmHg) will prevent or slow the progression of diabetes-related complications Figure 2 Incidence of progression to diabetic nephropathy during treatment with 150 mg of irbesartan daily, 300 mg of irbesartan daily or placebo in hypertensive patients with Type 2 diabetes and persistent microalbuminuria in the Irbesartan in patients with Type 2 diabetes and Microalbuminuria (IRMA-II) trial. 29 The difference between the placebo group and the 150 mg group was not significant, but the difference between the placebo group and the 300 mg group was significant (p<0.001 by the log-rank test) 
DETAIL
The Diabetics Exposed to Telmisartan And enalapriL (DETAIL) study is a randomised, doubleblind, parallel-group trial comparing the effects of telmisartan 80 mg and enalapril 20 mg on renal measures in 272 patients, 35-80 years old, with mild-to-moderate hypertension (SBP < 180 mmHg), Type 2 diabetes and nephropathy. 33 The primary endpoint is the change in glomerular filtration rate over the five-year treatment period.
Other parameters that will be assessed include change in the albumin excretion rate, the incidence of various clinical events (end-stage renal disease, MI, cerebrovascular accidents, and heart failure), and all-cause mortality. Although DETAIL has not been designed as a definitive outcome trial, it should provide some indication of the relative renoprotective effects of an ARB compared with an ACE-I in hypertensive patients with diabetes and nephropathy. Results are expected in 2005. Thus, RENAAL, IRMA II and IDNT have provided evidence that interrupting the RAAS with an ARB prevents the deterioration of renal function in patients with Type 2 diabetes mellitus and renal disease and that this benefit is independent of the effect on BP. However, since the protocols of these three trials did not allow concomitant use of ACE-Is, they did not examine the effects of dual RAAS blockade with an ACE-I plus an ARB.
DIRECT
Rather than focusing on renal function, the primary endpoint in the DIabetic REtinopathy Candesartan Trials (DIRECT) programme is the development or progression of another complication of diabetes, retinopathy. These three trials will randomise a total of 4,500 patients with Type 1 or Type 2 diabetes, who have normal BP and no evidence of renal disease, to treatment with candesartan cilexetil 16-32 mg or placebo. Enrolment into DIRECT commenced in 2001, and treatment will continue for three years.
NAVIGATOR
The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGA-TOR) trial is including subjects with impaired glucose tolerance. Such individuals have a high risk of developing diabetes and cardiovascular disease. A target of 7,500 patients, ≥ 50 years of age with established cardiovascular disease or ≥ 55 years with one cardiovascular risk factor, will be randomised to treatment with either valsartan or the oral anti-diabetic nateglinide (a prandial glucose regulator). The first phase of the study, due to complete in 2006, will evaluate whether either agent can prevent the development of overt diabetes in this pre-diabetic population. Secondly, the effect on cardiovascular morbidity and mortality will be evaluated after 1,000 cardiovascular events have been reported; this is expected to be in mid-2007.
Acute myocardial infarction
Despite advances in the management of acute MI, it continues to be accompanied by significant morbidity and mortality. A major contributor to this is post-MI neurohumoral activation. ACE-Is have become a mainstay of therapy in the early and chronic phases following MI. By producing more complete RAAS blockade, it is hypothesised that ARBs may offer similar or even additional benefits when administered to acute MI patients.Two large clinical trials are in progress to evaluate this theory (see Table 1 ).
OPTIMAAL
The effects of losartan and captopril on all-cause mortality in high-risk patients with acute MI was compared in the Optimal Therapy In Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) study. 34 This double-blind, parallel-group trial randomised 5,477 patients, ≥ 50 years of age, with left ventricular dysfunction following acute MI, to treatment with losartan 50 mg once-daily or captopril 50 mg three times daily (plus standard concomitant therapy, excluding other ARBs or ACE-Is). Treatment was initiated at hospitalisation and continued for a minimum of six months. Endpoints included all-cause mortality (primary endpoint), sudden cardiac death or resuscitated cardiac death, none of which were significantly different between the two treatments. However, there was a trend towards a slightly higher event rate in the losartan group, possibly reflecting the inadequacy of the 50 mg once-daily dose.
VALIANT
The VALsartan In Acute myocardial infarctioN Trial (VALIANT) also uses captopril as the active comparator. This ongoing study is assessing the effects of valsartan in an effective 160 mg twice-daily dose, versus captopril 50 mg three times daily, versus a combination of the two drugs on all-cause mortality (primary endpoint) and cardiovascular events in patients with evidence of left ventricular systolic dysfunction or heart failure following acute MI. 35, 36 VALIANT should, therefore, determine whether treatment with an ARB offers additional benefits over those achieved with an ACE-I in patients at high cardiovascular risk after MI. It should also help to determine whether dual inhibition of the RAAS with an ARB plus an ACE-I confers greater clinical benefits than either drug alone.
The study has randomised over 14,500 patients to valsartan 160 mg twice-daily, captopril 50 mg three times daily or a combination of the two drugs (valsartan 80 mg twice-daily, captopril 50 mg HOPE This is a critical study using an ACE-I, and should be reviewed briefly since it provides the basis for the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTAR-GET). The landmark HOPE trial was a randomised, double-blind, placebo-controlled study examining the effects of ramipril on major vascular events in high-risk patients. 52, [55] [56] [57] It enrolled 9,297 subjects, ≥ 55 years of age, with evidence of vascular disease or with diabetes plus one or more other cardiovascular risk factors, but with normal left ventricular function (i.e. no patients with heart failure). Patients were assigned to ramipril 10 mg or matching placebo for a mean of five years. However, the trial was stopped after a mean follow-up of 4.5 years because of a clear benefit of ramipril on cardiovascular outcomes.
Compared with placebo, ramipril reduced the risk of a primary cardiovascular event (cardiovascular death, stroke, or acute MI) by 22% (p<0.001), with significant reductions in each of the individual endpoints ( Table 4 ). The benefits of ramipril on the primary outcome were consistent across a range of subgroups examined. Ramipril also reduced the risk of a number of other clinical endpoints, including cardiovascular mortality, MI, stroke, all-cause mortality, revascularisation, complications of diabetes, hospitalisation for heart failure, heart failure, cardiac arrest, worsening angina, and new-onset diabetes (see Table 4 ).
One of the most interesting findings of HOPE was that the benefits associated with ramipril were greater than expected from the decreases in BP. Only 47.6% of patients were hypertensive at baseline (since HOPE was not specifically a hypertension trial), and the mean reduction in SBP/DBP with ramipril was stated to be a modest 3/2 mmHg. The authors claimed that this fall in BP might, at most, account for 40% of the observed risk reduction for stroke and 25% of the risk reduction for MI. 56 Ramipril could thus have independent protective effects on the vasculature and other target organs, possibly due to increasing plasma levels of bradykinin and other biologically active peptides. This conclusion is supported by the consistency of benefit of ramipril, in that it was effective in patients regardless of whether they were hypertensive or normotensive at baseline. The benefit of ramipril was also apparent over and above that of other drugs being used (aspirin, β-blockers, diuretics or lipid-lowering agents) that are known to have protective effects.
It is reasonable to speculate that interruption of the RAAS with ARBs might also offer improvements in clinical outcomes beyond their antihypertensive activity. Moreover, because ARBs selectively block the negative actions of Ang II mediated through AT 1 -receptors, yet preserve the apparent favourable effects mediated through AT 2 -receptors, 58, 59 the benefits might be greater than with ACE inhibition.The possibilities presented by combining an ACE-I with an ARB are even more intriguing. This is being explored in The ONTARGET Trial Programme.
Beyond HOPE -The ONTARGET Trial Programme
The ONTARGET Trial Programme comprises two parallel randomised, double-blind, outcome trials: the principal ONTARGET study and the parallel Telmisartan Randomized AssessmeNt Study in ACE-iNtolerant subjects with cardiovascular Disease (TRANSCEND). Involving approximately 28,400 patients from 793 sites in 40 countries over 5.5 years. The ONTARGET Trial Programme will be one of the most ambitious projects investigating the role of an ARB in the prevention of cardiovascular morbidity and mortality, and promises to represent a major milestone in defining the relative roles of ARBs and ACE-Is in the treatment of high-risk patients. Patient enrolment began in November 2001, and the studies are expected to complete in 2007. 
N P R O H I B I T E D
Telmisartan is the ARB employed in The ONTARGET Trial Programme. It is a non-peptide antagonist that selectively and insurmountably binds to the AT 1 -receptor without affecting other receptor systems involved in cardiovascular regulation, 60 has a half-life of approximately 24 hours (Table 5) , 61 and a single daily dose provides smooth and sustained BP control over the full 24hour period between doses. [62] [63] [64] [65] [66] This efficacy is maintained during the early morning period when the incidence of cardiovascular events peaks. 67 Like other ARBs, telmisartan has a side-effect profile similar to placebo. 61, 62, 64, 68, 69 
ONTARGET
The principal ONTARGET study will randomise 7,800 patients to each of three treatments: telmisartan 80 mg, ramipril 10 mg, or a combination of telmisartan 80 mg plus ramipril 10 mg. Patients are ≥ 55 years old and are at high risk of cardiovascular events (i.e. they have a history of coronary artery disease, peripheral vascular disease, stroke or recent transient ischaemic attack, or diabetes with end-organ damage). ONTARGET will not include patients with heart failure. The primary endpoint is a composite of cardiovascular death, stroke, acute MI, and hospitalisation for heart failure. Secondary endpoints include newly diagnosed heart failure, revascularisation procedure, newly diagnosed diabetes, cognitive decline/ dementia, nephropathy, and new-onset atrial fibrillation.
The hypotheses being tested are: i) that telmisartan is as effective as ramipril at improving clinical outcomes, but is better tolerated, and ii) that a combination of telmisartan plus ramipril will offer better end-organ protection than either agent alone due to greater RAAS blockade, improved haemodynamic control, and preservation of any benefits associated with increased bradykinin levels.
TRANSCEND
The parallel placebo-controlled TRANSCEND trial will examine the protective effects of telmisartan in patients who are eligible for the main ONTAR-GET study, but cannot tolerate ACE-Is (e.g. due to cough). Current internationally regarded hypertension guidelines already cite ACE-I-induced cough as a compelling indication for ARB treat-ment. 1, 70 TRANSCEND is expected to be the largest cardiovascular protection trial conducted in patients intolerant of ACE-Is.
TRANSCEND will aim to randomise 5,000 ACE-I-intolerant patients to either telmisartan 80 mg or placebo. Patients with proteinuria or microalbuminuria will be excluded, because results from IDNT, 31 IRMA II, 29 and RENAAL 28 have shown that placebo therapy would be unethical in this population. Endpoints and timelines are the same as for the principal ONTARGET study.
Conclusions
As well as the key role of ACE-Is in the management of hypertension, 1, 70 studies indicate that they have vasculoprotective and renoprotective effects, improving outcomes of patients with a variety of cardiovascular disorders. For example, ramipril is also indicated for heart failure, post-MI prevention of disease progression in patients with heart failure, and reducing the risk of stroke, MI, and cardiovascular death in high-risk patients aged ≥ 55 years. Nevertheless, ACE-Is have limitations. Ang II concentrations can return to pretreatment levels with long-term ACE-I use, due to the stimulation of ACE-independent pathways, the so-called 'Ang II escape'. There are also class-specific sideeffects, such as cough and angioedema, which cause a substantial proportion of patients to discontinue treatment.
By acting at the receptor level,ARBs should, at least theoretically, provide more complete RAAS blockade than ACE-Is. ARBs are also better tolerated, with side-effect profiles similar to placebo. Evidence to date, although limited, suggests that ARBs will be useful alternatives to ACE-Is for improving clinical outcomes in a range of highrisk patients. Results of a number of ongoing clinical trials should provide a definitive answer on the relative place of ARBs and ACE-Is in clinical practice. The next few years promise to be an exciting time as these various trials continue and the results help to define the relative place of ARBs and ACE-Is in clinical practice.
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